Compass Therapeutics is expected to report a Q3 2026 loss of $0.12 per share on consensus revenue of $0.23 million, with its $0.84 current price trading well below the $5.83 average analyst target.
The central focus for investors is the Biologics License Application (BLA) submission timeline for tovecimig, the company's lead candidate for biliary tract cancer.
Analysts are seeking clarity on the regulatory path following recent Phase 2/3 data and potential feedback from the FDA regarding survival-benefit requirements. The report will also provide a vital update on the company’s cash runway, which is currently anticipated to support operations into 2028 based on current research spending.